Find a study
Browse recruiting studies near you — free to check, always your choice.
287 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- DepressionAnxiety
Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease
Testing whether therapy sessions can help teens and young adults with sickle cell cope with
📍 Children's Hospital Los Angeles · Los Angeles, CA · Get directions →
The current study seeks to build on previous research that demonstrates the efficacy of Acceptance and Commitment Therapy in combating stigma by investigating the feasibility and acceptability of a protocol to support Black adolescents and young adults in coping with race related stress. The study will consist of a small, purposeful, non-randomized sample (N = 30) of clients enrolled into a 10-session Acceptance and Commitment Therapy group.
- Depression
Inflammation and Depression in People With HIV
Testing whether inflammation affects brain circuits linked to depression symptoms in people with HIV
📍 Grady Memorial Hospital · Atlanta, GA · +1 more US site · Get directions →
The purpose of this 10-week, double-blind, placebo-controlled study is to determine whether inflammation impacts reward and motor neural circuitry to contribute to depressive symptoms like anhedonia and psychomotor slowing in people with Human Immunodeficiency Virus (HIV) and depression. Sixty male and female patients with HIV who have depression, anhedonia and high inflammation and are stable on effective treatment for their HIV will be randomized to receive either the anti-inflammatory drug baricitinib or a placebo for 10 weeks.
- Depression
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Testing lumateperone added to usual care for major depressive disorder
📍 University of Alabama at Birmingham · Huntsville, AL · +24 more US sites · Get directions →
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.
- Depression
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Testing azetukalner compared with a placebo for adults with major depression
📍 Harmonex Neuroscience Research · Dothan, AL · +33 more US sites · Get directions →
X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
- Kidney disease
Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis
Testing amino acid supplements during hemodialysis for fatigue and thinking in end-stage kidney
📍 The University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →
The study will test and compare the efficacy of a single essential amino acid valine with a combination of essential amino acids (EAA) supplement on fatigue, frailty, and cognitive function in end-stage kidney disease (ESKD) patients undergoing hemodialysis (HD) treatment.
- Kidney disease
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Testing the safety and tumor effects of GI-102 alone and with cancer drugs in people with advanced
📍 Mayo Clinic in Arizona · Scottsdale, AZ · +4 more US sites · Get directions →
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.
- Depression
5-HTP and Creatine for Depression R33 Phase
Testing whether 5-HTP and creatine added to treatment helps depression
📍 University of Utah Department of Psychiatry · Salt Lake City, UT · Get directions →
This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression. Subjects will be randomized between 5-HTP 100mg BID + creatine 5g daily, 5-HTP 200mg BID + creatine 10g daily, vs double placebo, for 8 weeks.
- Kidney disease
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
Testing whether empagliflozin is safe and helps children with chronic kidney disease
📍 University of Alabama at Birmingham · Birmingham, AL · +29 more US sites · Get directions →
This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medicine called empagliflozin helps children and adolescents with CKD.
- Depression
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
Testing whether a brain receptor change affects ketamine’s effect on depression
📍 Yale University · New Haven, CT · Get directions →
The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.
- Kidney disease
Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD
Studying how blood vessel and nerve control during exercise works in people with chronic kidney
📍 Emory Clinic · Atlanta, GA · +1 more US site · Get directions →
The goals of this project are to investigate the mechanisms and potential therapies related to exercise capacity in persons with chronic kidney disease (CKD).
- Depression
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Testing azetukalner versus a placebo for bipolar depression in adults
📍 Noble Clinical Research · Tucson, AZ · +27 more US sites · Get directions →
X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a depressive episode (bipolar depression).
- Sickle cell disease
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
Testing different doses of DISC-3405 to check safety in sickle cell disease
📍 University of Alabama at Birmingham · Birmingham, AL · +6 more US sites · Get directions →
This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.
- Depression
Intravenous Ketamine for Treatment-Resistant Depression
Testing how a 40-minute IV ketamine infusion affects brain and mood in adults with hard-to-treat
📍 Mayo Clinic in Rochester · Rochester, MN · Get directions →
The purpose of this study is to to evaluate the relationships between peak (% change from baseline) central GABA and Glu levels during a 40-min IV ketamine or normal saline infusion utilizing fMRS, and change in peripheral GABA and Glu levels from baseline to 24-hr postinfusion utilizing LCMS, with baseline to 24-hr post-infusion change in depression (MADRS) in 30 TRD adults.
- Depression
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
Testing how dimethyltryptamine affects safety and depression symptoms
📍 Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, · West Haven, CT · Get directions →
The goal of this phase 1 study is to investigate the safety and efficacy of dimethyltryptamine (DMT) in individuals with depression and healthy controls. We hypothesize that administration of DMT will result in decreases in depression, associated symptoms, and neuroplastic changes in depressed subjects.
- Depression
Study of ALTO-300 in MDD
Testing whether ALTO-300 works better than placebo for depression
📍 Site 200 · Phoenix, AZ · +39 more US sites · Get directions →
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
- DepressionAnxiety
Personalized Brain Stimulation to Treat Chronic Concussive Symptoms
Testing personalized brain stimulation for ongoing concussion symptoms
📍 UCLA · Westwood, Los Angeles, CA · Get directions →
The goal of this study is to investigate a new treatment for chronic symptoms after concussion or mild traumatic brain injury in people aged 18-65 years old. Chronic symptoms could include dizziness, headache, fatigue, brain fog, memory difficulty, sleep disruption, irritability, or anxiety that occurred or worsened after the injury.
- Depression
Ketamine Alcohol (in Treatment-Resistant Depression)
Testing ketamine infusions for depression in people who also have alcohol use risk
📍 University of Iowa Health Care · Iowa City, IA · Get directions →
A single subanesthetic dose infusion of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has rapid and robust antidepressant effects in patients with treatment-refractory major depressive disorder (TRD). A family history of an alcohol use disorder (Family History Positive, FHP) is one of the strongest identified predictors of an improved antidepressant response to ketamine.
- Depression
Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department
Testing whether a low-dose ketamine IV treatment is safe and workable in the ER for people with
📍 University of Kansas Strawberry Hill Campus · Kansas City, KS · +1 more US site · Get directions →
There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who present to the ED with suicidal ideation.
- High blood pressureKidney disease
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
Testing how adding a diabetes medicine to baxdrostat affects urine protein in people with chronic
📍 Research Site · Surprise, AZ · +17 more US sites · Get directions →
International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.
- Depression
A Randomized Neuroimaging Trial of Psilocybin in Depression
Testing whether psilocybin changes brain activity in people with depression compared with placebo
📍 Sunnybrook Health Sciences Centre · Toronto, Ontario · Get directions →
The goal of this neuroimaging clinical trial is to test whether psilocybin produces significant immediate changes in functional brain activity in networks associated with mood regulation and depression compared to placebo in patients with depression. The trial aims to determine if psilocybin: 1.
- Depression
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
Testing a medicine versus placebo for safety and effectiveness in adults with major depression
📍 Collaborative Neuroscience Network · Garden Grove, CA · Get directions →
This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder
- Depression
Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression
Testing how one-time exercise and ibuprofen affect bipolar depression symptoms
📍 Laureate Institute for Brain Research · Tulsa, OK · Get directions →
This is a 2x2, within-subjects, cross-over trial to test the anti-depressant effects of acute exercise in 20 participants with bipolar depression. Participants will complete four experimental sessions, two with an exercise challenge and two with a resting control condition in a counterbalanced order.
- DepressionAnxiety
ACT for Individuals With MNCD and Their Care Partners
Testing acceptance commitment therapy for depression and anxiety in dementia
📍 Texas Tech University Plaza Building · Lubbock, TX · Get directions →
This project aims to implement and evaluate a dyadic intervention (i.e., acceptance commitment therapy) for persons with AD/ADRD and their care partners. We hypothesize the intervention will be feasible, acceptable, and show preliminary efficacy of the dyadic interveniotns.
- Heart / cardiovascular diseaseKidney disease
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Testing whether orforglipron changes heart outcomes in adults with heart disease and/or kidney
📍 Instituto de Investigaciones Clínicas Bahia Blanca · Bahía Blanca, · Get directions →
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
- Kidney disease
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
Comparing how two beta-blockers work in hemodialysis patients on heart outcomes
📍 VA Long Beach Healthcare System, Long Beach, CA · Long Beach, CA · +7 more US sites · Get directions →
The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.
- Sickle cell disease💵 May compensate
Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease
Testing higher doses of VAS-101 in people with stable sickle cell disease
📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →
Background: Sickle cell disease (SCD) is an inherited blood disorder. The disease affects the ability of red blood cells to carry oxygen.
- Kidney disease
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
Testing a 12-week diabetes medicine combination in kidney transplant patients with kidney disease
📍 Toronto General Hospital · Toronto, Ontario · Get directions →
The study aims to determine the short-term efficacy, mechanisms and safety of 12 weeks of dapagliflozin and semaglutide combination therapy in 20 KTR, with and without T2D.
- Depression
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
Testing changes in depression symptoms and side effects from an oral medicine
📍 Harmonex /ID# 277517 · Dothan, AL · +32 more US sites · Get directions →
Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focus on activities, tiredness, changes in eating habits, and aches and pains.
- Depression
RCT of Psilocybin-assisted CBT for Depression
Testing psilocybin with cognitive-behavioral therapy for depression
📍 UCLA Semel Institute · Los Angeles, CA · Get directions →
The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2) optimize CBT to most effectively integrate the psilocybin experience with psychotherapy and (3) examine the clinical benefit of psilocybin as an adjunct to cognitive-behavioral therapy (CBT) for major depressive disorder. This study is a randomized, two-arm, fixed dose trial that will test the feasibility, acceptability, and participant and therapist adherence to PA-CBT.
- Depression
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
Testing a drug called ACP-211 for adults with depression who did not improve with antidepressants
📍 University of Alabama at Birmingham · Birmingham, AL · +20 more US sites · Get directions →
The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD). The main questions the study aims to answer are: * Does ACP-211 work better than a placebo (a look-alike capsule with no medicine) to reduce symptoms of depression?
- Depression
Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
Comparing pramipexole and escitalopram for depression in people with HIV
📍 Alabama CRS · Birmingham, AL · +24 more US sites · Get directions →
A phase II, randomized, open-label, two-arm clinical trial evaluating the safety and efficacy of pramipexole extended release (ER) versus escitalopram for the treatment of major depressive disorder (MDD) and comorbid MDD with mild neurocognitive disorder (MND) in persons with HIV (PWH). Participants will be assessed comprehensively and briefly at intercurrent visits to monitor for toxicity, response to therapy, and to assess for dose changes.
- DepressionAnxiety
iTBS+D-Cycloserine for Youth Suicide
Testing a treatment for depression and anxiety to reduce youth suicide risk
📍 University of Calgary · Calgary, Alberta · Get directions →
Background and Rationale: Suicide is the second leading cause of death in Canadian Emerging Adults (EAs; 18-24yrs). Current treatments for suicidal thoughts and behaviors are limited and novel treatments are required to save lives.
- Kidney disease
Acute Equol Supplementation and Vascular Function in Women With and Without CKD
Testing whether taking equol affects blood vessel function in women with or without CKD
📍 University of Colorado Anschutz Medical Campus · Aurora, CO · Get directions →
The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk.
- Depression
Psilocybin rTMS for Treatment Resistant Depression
Testing whether psilocybin paired with a brain stimulation treatment is safe in people with
📍 Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600 · Austin, TX · Get directions →
The purpose of this study is to determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT) in individuals with treatment-resistant major depressive disorder.
- Depression
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
Testing whether DT-101 treats depression in adults compared with placebo
📍 Draig Clinical Site · Bentonville, AR · +22 more US sites · Get directions →
The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo.
- Depression
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
Testing whether blocking inflammation with an IV medicine affects thinking speed in people with
📍 Massachusetts General Hospital · Boston, MA · Get directions →
This study is a mechanistic randomized controlled trial that investigates whether inhibition of tumor necrosis factor signaling via intravenous infusion of infliximab improves psychomotor speed and executive functioning in depressed individuals who exhibit an inflammatory phenotype.
- Kidney disease
A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD)
Testing the safety of an intravenous medicine in adults with chronic kidney disease
📍 SouthCoast Research Center, Inc. · Miami, FL · +1 more US site · Get directions →
The goal of this clinical trial is to learn about the safety (good or bad) of giving two AION-301 intravenous (IV) infusions, in adults with Stage 3 Chronic Kidney Disease (CKD). It will also help to learn if AION-301 reduces the symptoms of CKD and/or progression.
- Sickle cell disease
A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)
Testing the safety and how an oral carbon monoxide liquid works in sickle cell disease
📍 Cevaxin - The Panama Clinic · Panama City, · Get directions →
This is a multi-center, open label Phase 2a clinical trial in subjects with sickle cell disease to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of HBI-002, an orally administered liquid containing carbon monoxide (CO), with doses daily for 14 days.
- Depression
Psilocybin for Treatment-Resistant Depression in Autism
Testing psilocybin plus talk therapy for depression in autistic adults
📍 Centre for Addiction and Mental Health · Toronto, Ontario · Get directions →
We propose a first-of-its-kind open-label clinical trial to investigate the feasibility, tolerability, and safety of administering psilocybin in autistic adults with treatment-resistant depression (TRD). In this study, 20 participants (intellectually able and fluent-speech adults) with autism and co-occurring TRD will receive around 20 hours of manualized psychotherapy that has previously been used with psilocybin (Agin-Liebes et al., 2020).
- DepressionAnxiety
Perinatal Depression & Anxiety (PDA) and Maternal Gut Microbiome
Studying how gut bacteria in pregnant people relates to depression and anxiety
📍 Sunnybrook Health Science Center · Toronto, Ontario · Get directions →
Perinatal depression and anxiety (PDA) are the leading causes of maternal mortality in developed countries. Women with a history of depression have a 20 fold higher risk of PDA at subsequent pregnancies.
- Sickle cell disease
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
Testing whether a low dose of ketamine helps treat sickle cell pain in children and young adults
📍 Harbor UCLA Medical Center · Torrance, CA · Get directions →
The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain. In this study, we will compare the outcomes (such as pain scores) in persons who receive standard of care pain medicine (an opioid such as morphine) plus a low dose (amount) of ketamine to those who receive only standard of care pain medicine.
- DepressionAnxiety
Nebulized Ketamine for the Treatment of Major Depressive Disorder
Testing a breathing mist of ketamine to reduce symptoms of major depression
📍 Maimonides Medical Center · Brooklyn, NY · Get directions →
This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.
- Depression
Allopregnanolone (Zuranolone) in Post-stroke Depression
Testing whether a pill called zuranolone is safe and helps depression after a stroke
📍 Duke South Neurology Clinic 1L · Durham, NC · Get directions →
The goal of this Phase II clinical trial is to learn if the oral synthetic allopreganolone analog (zuranolone) is safe to take and is well tolerated by stroke survivors experiencing moderate to severe post-stroke depression and if it will help with the symptoms of depression. The main questions it will aim to answer are: * Is zuranolone safe to take by participants who have moderate to severe post-stroke depression?
- Kidney disease
Intradialytic Exercise Combined With Creatine Monohydrate in Patients With Chronic Kidney Disease Undergoing Hemodialysis.
Testing whether exercise during dialysis and creatine help people with chronic kidney disease
📍 IMSS-Bienestar State Haemodialysis Centre · Colima, Coliima · Get directions →
This study aims to evaluate the effects of creatine monohydrate supplementation and an intradialytic exercise program on body composition, biochemical parameters, and functional capacity in patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis. The study will compare the independent and combined effects of these interventions over an 8-week period to determine their potential benefits in this patient population.
- DepressionAnxiety
Leveraging mHealth to Promote Opioid Use Recovery and Mental Health Among Residents of a Medium-Sized Midwestern City
Testing whether a phone-based program supports opioid recovery and mental health
📍 Washington University School of Medicine · St Louis, MO · Get directions →
The sequential trial compares recovery and mHealth engagement outcomes among Black participants who participated in the mHealth intervention uMAT-R or uMAT-R + enhanced community engagement. The mHealth intervention seeks to support people in various stages of recovery who are also seeking other forms of substance use treatment.
- Depression
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Testing azetukalner against a placebo for major depression in adults
📍 IMA Clinical Research Phoenix · Phoenix, AZ · +39 more US sites · Get directions →
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
- Sickle cell disease
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
Testing rilzabrutinib for safety and effectiveness in sickle-cell disease
📍 University of Alabama at Birmingham- Site Number : 8400003 · Birmingham, AL · +15 more US sites · Get directions →
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-adaptive, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD). Study details include: * Study duration: a 52-week double-blind period (Part A), followed by an open-label LTE period (Part B).
- Depression
Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine
Testing how ketamine changes brain chemicals in people with depression
📍 University of Pennsylvania · Philadelphia, PA · Get directions →
In the treatment of Major Depressive Disorder (MDD), ketamine can produce rapid but short-lasting improvements in mood. In order to develop a new generation of treatments with rapid and sustained efficacy, a better understanding of the mechanism of action is urgently needed.
- Depression
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Testing a deuterated psilocin-related medicine for major depression
📍 UAB Psychiatry and Behavioral Neurology · Birmingham, AL · +32 more US sites · Get directions →
The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD. For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/
- DepressionAnxiety
Integrating Inuit Knowledge Principles in Multi-Level Mental Health Clinical Trials
Testing whether eating more country foods and cultural activities help Inuit adults with depression
📍 Aqqiumavvik Society · Arviat, Nunavut · Get directions →
This study is looking at how eating more country foods affects mental health among Inuit men and women in Arviat, NU. The goal is to evaluate if eating more of these foods helps people feel less depressed or anxious, and whether being part of food-gathering and cultural activities also makes a difference.
- Depression
Stratified Pharmacological Approaches for Regulating Circuit-Level Effects
Testing how pramipexole affects depression symptoms and brain circuits
📍 Stanford University · Palo Alto, CA · Get directions →
This research study aims to understand how people with depression respond to the medication pramipexole and to determine whether clinical response differs depending on the function of specific circuits in the brain. The investigators hope to learn which circuits are involved in depression and how these circuits interact with pramipexole to affect mood, behavior, and cognition.
- Depression
DBS for Depression
Testing whether deep brain stimulation is safe and feasible for severe depression that hasn’t
📍 Zucker Hillside Hospital · Queens, NY · Get directions →
The goal of this clinical trial is to demonstrate the feasibility and safety of deep brain stimulation in treatment resistant depression. The main questions it aims to answer are: * Is deep brain stimulation effective in treating treatment resistant depression?
- Depression
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Testing brenipatide to see if it delays return of major depression symptoms
📍 Accellacare - Moorpark · Moorpark, CA · +31 more US sites · Get directions →
This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms. The trial is divided into three periods as follows: a screening period that will last approximately 1 month, a treatment period that will last a minimum of 12 months, and the follow up period that will last approximately 2 months.
- Sickle cell disease
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
Testing whether extra arginine lowers pain in children with sickle cell
📍 Children's Healthcare fo Atlanta at Hughes Spalding · Atlanta, GA · +1 more US site · Get directions →
The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking treatment for vaso-occlusive painful events (VOE) will decrease pain scores, decrease need for pain medications or decrease length of hospital stay or emergency department visit.
- DepressionAnxiety
Creatine for Depressed Male and Female Methamphetamine Users
Testing whether creatine helps depression and anxiety in people who use meth
📍 Montana State University College of Nursing (Missoula campus) · Missoula, MT · Get directions →
* Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression
- Sickle cell disease
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
Testing a once-daily mouth medicine in teens with sickle cell disease
📍 The Hospital for Sick Children · Toronto, Ontario · Get directions →
This study is being done to learn about etavopivat, a once a day medicine taken by mouth in adolescents with sickle cell disease. The main goals are to study safety and how long etavopivat stays in the bloodstream, while also studying if there are benefits from taking etavopivat.
- Depression
Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression
Testing whether donor stem cells are safe and helpful for hard-to-treat bipolar depression
📍 The University of Texas Health Science Center at Houston · Houston, TX · Get directions →
The overall objective of the investigators is to assess the therapeutic efficacy and tolerability of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow for treatment of treatment-resistant bipolar depression patient (TRBD).
- Kidney disease
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
Testing etelcalcetide in children with kidney disease on dialysis
📍 Childrens Hospital of Los Angeles · Los Angeles, CA · +9 more US sites · Get directions →
This is a phase 3 trial of etelcalcetide in pediatric participants with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) on hemodialysis.
- Kidney disease
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
Testing how a diabetes medicine in the bloodstream changes in kidney disease
📍 Floridian Clinical Research, LLC · Miami Lakes, FL · +1 more US site · Get directions →
The purpose of the study is to assess the amount of Eloralintide (LY3841136) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants. The study drug will be administered subcutaneously (SC) (under the skin).
- Kidney disease
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
Testing safety and effects on urine protein in adults with APOL1 kidney disease
📍 Research Site · Decatur, AL · +39 more US sites · Get directions →
This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease
- Showing the first 60 of 287. Add filters or a location to narrow down.